Nuvalent, Inc. $NUVL Stock Holdings Trimmed by First Turn Management LLC

First Turn Management LLC decreased its position in shares of Nuvalent, Inc. (NASDAQ:NUVL) by 6.6% during the fourth quarter, HoldingsChannel reports. The firm owned 368,697 shares of the company’s stock after selling 26,057 shares during the period. Nuvalent makes up approximately 4.2% of First Turn Management LLC’s holdings, making the stock its 7th biggest holding. First Turn Management LLC’s holdings in Nuvalent were worth $37,087,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in NUVL. AQR Capital Management LLC raised its position in Nuvalent by 64.8% during the first quarter. AQR Capital Management LLC now owns 9,874 shares of the company’s stock valued at $700,000 after purchasing an additional 3,881 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Nuvalent by 54.4% during the first quarter. Goldman Sachs Group Inc. now owns 453,620 shares of the company’s stock valued at $32,171,000 after purchasing an additional 159,873 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Nuvalent by 8.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 149,941 shares of the company’s stock valued at $10,634,000 after purchasing an additional 12,123 shares in the last quarter. Intech Investment Management LLC raised its position in Nuvalent by 28.7% during the first quarter. Intech Investment Management LLC now owns 19,262 shares of the company’s stock valued at $1,366,000 after purchasing an additional 4,293 shares in the last quarter. Finally, Prudential Financial Inc. purchased a new stake in Nuvalent during the second quarter valued at about $412,000. Hedge funds and other institutional investors own 97.26% of the company’s stock.

Insiders Place Their Bets

In related news, CEO James Richard Porter sold 30,000 shares of the business’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $88.53, for a total transaction of $2,655,900.00. Following the transaction, the chief executive officer owned 324,879 shares in the company, valued at $28,761,537.87. The trade was a 8.45% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Alexandra Balcom sold 11,430 shares of the business’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $105.21, for a total value of $1,202,550.30. Following the transaction, the chief financial officer owned 85,533 shares in the company, valued at approximately $8,998,926.93. This represents a 11.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 126,953 shares of company stock worth $12,612,264 in the last quarter. 5.02% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Lifesci Capital downgraded Nuvalent from an “outperform” rating to a “hold” rating and set a $124.00 price target on the stock. in a research report on Tuesday, June 9th. Robert W. Baird set a $122.85 target price on Nuvalent in a research note on Tuesday. Leerink Partners set a $165.00 target price on Nuvalent in a research note on Wednesday, June 3rd. Piper Sandler lowered Nuvalent from an “overweight” rating to a “neutral” rating and set a $124.00 target price for the company. in a research note on Tuesday. Finally, Stifel Nicolaus set a $124.00 target price on Nuvalent in a research note on Tuesday. Five equities research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Nuvalent has an average rating of “Hold” and a consensus target price of $131.15.

Nuvalent Trading Down 0.2%

NASDAQ NUVL opened at $123.25 on Friday. Nuvalent, Inc. has a 1-year low of $71.13 and a 1-year high of $123.62. The stock has a 50-day moving average of $104.21 and a 200-day moving average of $103.45. The firm has a market cap of $9.74 billion, a PE ratio of -20.34 and a beta of 1.15.

Nuvalent (NASDAQ:NUVL) last released its earnings results on Thursday, May 7th. The company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.04). During the same quarter in the prior year, the company earned ($1.18) earnings per share. As a group, equities research analysts forecast that Nuvalent, Inc. will post -5.74 earnings per share for the current fiscal year.

Nuvalent News Roundup

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: GSK’s purchase underscores strong strategic demand for Nuvalent’s oncology assets, especially its selective tyrosine kinase inhibitor programs, which supports the view that the company’s pipeline has major pharma value. Reuters article on GSK deal
• Positive Sentiment: Market commentary and analyst coverage suggest the acquisition is strategically important for GSK’s oncology rebuild, reinforcing confidence that the transaction is meaningful and likely to close. Reuters article on GSK oncology rebuild
• Neutral Sentiment: Several analyst downgrades followed the takeover announcement, but their revised price targets remain close to the deal price, so the impact on the stock appears limited. Analyst downgrade coverage
• Neutral Sentiment: Law firms have begun reviewing whether the sale process and price were fair, which could create headline noise but does not change the announced terms. Business Wire article on investigation
• Negative Sentiment: CEO James Richard Porter sold 30,000 shares, which may slightly weigh on sentiment by suggesting insiders have been reducing exposure ahead of the transaction. SEC insider filing

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.